The Myelin Repair Foundation has spent $10 million so far to identify 18 new drug leads for multiple sclerosis. The non-profit foundation says it plans to roll out the two best leads to pharma companies this summer, hoping for a licensing deal that will swiftly advance a new drug for MS.
The Foundation is helping blaze a path in new drug research, taking millions of dollars in donations and advancing experimental new therapies to the point that a drug company would want to in-license them for commercial development. And the Foundation is prepared to take a smaller payback in exchange for a faster development path.
- check out the report in the San Francisco Chronicle